Prior to tocilizumab treatment, elevated IL-6 levels suppressed CYP3A4 activity in RA patients, leading to reduced simvastatin clearance and increased plasma exposure of simvastatin (Figure 3, left panel). This evidence concerns the gene CYP3A4 and rheumatoid arthritis.